Page last updated: 2024-08-18

thiophenes and Acute Coronary Syndrome

thiophenes has been researched along with Acute Coronary Syndrome in 394 studies

Research

Studies (394)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	68 (17.26)	29.6817
2010's	326 (82.74)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cosentino, F; Grobbee, DE; Lincoff, AM; Mellbin, L; Morici, N; Nozza, A; Perrone Filardi, P; Ponticelli, C; Savonitto, S; Schrieks, IC; Schwartz, GG; Stähli, BE; Tardif, JC	1
Ji, JZ; Jia, YM; Tai, T; Xie, HG	1
Cavallini, C; Cosentino, F; Eijkemans, MJ; Ferri, M; Grobbee, DE; Lambers Heerspink, HJ; Lincoff, AM; Malmberg, K; Morici, N; Morocutti, G; Murena, E; Nozza, A; Perrone Filardi, P; Ryden, L; Savonitto, S; Schrieks, IC; Schwartz, GG; Stähli, BE; Tardif, JC; Toyama, T	1
Buse, JB; Grobbee, DE; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A	1
Buse, JB; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A	1
Angiolillo, DJ; Bass, TA; Desai, B; Ferreiro, JL; Guzman, LA; Rollini, F; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M	1
Angiolillo, DJ; Rollini, F	1
Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB	1
Alexopoulos, D; Davlouros, P; Mavronasiou, E; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I	1
Fernández, D; Heras, M; Penela, D	1
Braunwald, E; Burton, P; Gibson, CM; Kiss, RG; Mega, JL; Murphy, SA; Parkhomenko, A; Plotnikov, AN; Tendera, M; Widimsky, P	1
White, HD; Wong, CK	1
Wang, H; Wang, WE; Wang, X; Zeng, C	1
Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K	1
Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW	1
Coleman, CI; Limone, BL	2
Alessi, MC; Beguin, S; Bonnet, G; Bonnet, JL; Cayla, G; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Quilici, J	1
Alexopoulos, D; Davlouros, P; Hahalis, G; Perperis, A; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I	1
Enar, R	1
Göddertz, R	1
Dixon, S; Grossman, M; Gurm, HS; Lalonde, T; Moscucci, M; Riba, AL; Sandhu, A; Seth, M; Share, D; Wohns, D	1
Atar, D; Serebruany, V	1
Effron, MB; McCollam, PL; Molife, C; Nordstrom, BL; Simeone, JC; Ye, X; Zhao, Z	1
Braunwald, E; Gibson, CM; Gotcheva, N; Mega, JL; Murphy, SA; Plotnikov, A; Ruda, M; Wiviott, SD	1
Alexopoulos, D; Davlouros, P; Hahalis, G; Kakkavas, A; Koutsogiannis, N; Mavronasiou, E; Moulias, A; Xanthopoulou, I	1
DiNicolantonio, JJ; Serebruany, VL	1
Huber, K; Lip, GY	1
Kaul, S; Krantz, MJ	1
Conde, D; Elissamburu, P; Lalor, N; Rodriguez, L; Trivi, M	2
Christ, G; Francesconi, M; Grohs, K; Hafner, T; Podczeck-Schweighofer, A; Siller-Matula, JM; Wilhelm, E	1
Giugliano, RP; Shimada, YJ	1
Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ	1
Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL	1
Geller, BJ; Gibson, CM; Guo, J; Hoffman, EB; Mega, JL; Morrow, DA; Ruff, CT	1
Aronow, WS	2
Alessi, MC; Beguin, S; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Pons, C; Quilici, J	1
Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Collet, JP; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB	1
Dinicolantonio, JJ; Norgard, NB	1
Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD	1
Bennaghmouch, N; Ten Berg, JM	1
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cuisset, T; Grosdidier, C; Lambert, M; Loosveld, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J	1
Gross, L; Massberg, S; Orban, M; Sibbing, D	1
Aylward, PE; Sinhal, AR	1
Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I	1
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G	1
Keaney, JF	1
Angioli, P; Bolognese, L; Cayla, G; Costigan, TM; Dudek, D; Goedicke, J; Goldstein, P; Hamm, C; Jakubowski, JA; Legutko, J; Miller, DL; Montalescot, G; Motovska, Z; Niethammer, M; Silvain, J; Tanguay, JF; ten Berg, JM; Vicaut, E; Visconti, LO; Widimsky, P	1
Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Tardif, JC; Wedel, H; Weichert, A	1
Antman, EM; Braunwald, E; Cannon, CP; Giugliano, RP; Mogabgab, O; Sabatine, MS; Sloan, S; Wiviott, SD	1
Angiolillo, DJ; Cardillo, TE; Diodati, JG; Effron, MB; Fisher, HN; French, JK; Fung, AY; Henneges, C; Saucedo, JF	1
Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD	1
Adsett, G; Jayasinghe, R; Markham, R	1
Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD	1
Barnay, P; Berbis, J; Bessereau, J; Bonello, L; Camilleri, E; Dignat-George, F; Frère, C; Helal, O; Laine, M; Michelet, P; Paganelli, F; Pansieri, M; Ronsin, O; Toesca, R	1
Damman, P; Eriksson, P; Erlinge, D; James, SK; Koul, S; Lagerqvist, B; Varenhorst, C	1
Brennan, T; Canestaro, WJ; Chaplin, D; Choudhry, NK; Desai, NR; Kyrychenko, P; Martell, LA; Matlin, OS	1
Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Lambert, M; Morange, P; Pankert, M; Quilici, J; Verdier, V	2
Verheugt, FW	1
Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD	1
Kreutz, R	1
Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I	1
Angiolillo, DJ; Antoniucci, D; Bernlochner, I; Hamm, C; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Neumann, FJ; Richardt, G; Ruf, J; Schömig, G; Schühlen, H; Schulz, S; Schunkert, H; von Merzljak, B	1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C	1
Goto, S; Tomita, A	1
Gasparovic, H; Petricevic, M	1
Alessi, MC; Bonnet, JL; Cuisset, T; Quilici, J	1
Darvish-Kazem, S; Douketis, JD; Liew, A	1
Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK	1
Hirschl, MM	1
Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A	1
Gupta, K; Singh, D; Vacek, JL	1
Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA	1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ	1
Plosker, GL	1
Angiolillo, DJ; Capodanno, D	1
Coons, JC; Harris, J; Schwier, N; Seybert, AL	1
Aronson, D	1
Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK	1
Sabouret, P; Taiel-Sartral, M	1
Meddahi, S; Samama, MM	1
Bassand, JP	1
Hviid, A; Pasternak, B; Svanström, H	1
Delzor, F; Nanau, RM; Neuman, MG	1
Giugliano, RP; Reddy, P	1
Antoniucci, D; De Luca, G; Marino, P; Parodi, G; Schaffer, A; Suryapranata, H; Verdoia, M	1
Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Svensson, A; Tardif, JC; Volz, D; Wedel, H; Weichert, A	1
Thachil, J	1
Angiolillo, DJ; Cardillo, TE; Diodati, JG; Duvvuru, S; Effron, MB; Fisher, HN; Henneges, C; Jakubowski, JA; Lipkin, FR; Saucedo, JF; Sundseth, SS; Walker, JR	1
Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU	1
Mearns, BM	1
Asrar ul Haq, M; van Gaal, WJ	1
Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H	1
Bangalore, S; Biondi-Zoccai, G; Cerrato, E; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Fuchs, FD; Lavie, CJ; Meier, P; Niazi, AK; Norgard, NB; O'Keefe, JH; Packard, KA; Serebruany, VL	1
Elosua, R; Marrugat, J; Vila, J	2
Catalá-López, F	1
Fortmann, SD; Serebruany, VL	1
Massberg, S; Sibbing, D	1
Harrington, RA; Himmelmann, A; Steg, PG; Storey, RF; Wallentin, L	1
Bataille, V; Carrié, D; Garcia, C; Lhermusier, T; Lipinski, MJ; Mejean, S; Murat, G; Sié, P; Voisin, S	1
Droppa, M; Gawaz, M; Geisler, T; Karathanos, A; Metzger, J; Müller, K; Rath, D; Schäffeler, E; Schwab, M; Stimpfle, F; Tavlaki, E; Winter, S	1
Ahrens, I; Bode, C	2
Ossei-Gerning, N; Shivu, GN	1
Cohen, M; Iyer, D	1
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Vanassche, T; Weitz, JI	1
Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Gurbel, PA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Sritara, P; White, HD; Zamoryakhin, D	1
Alexopoulos, D; Bampouri, T; Gkizas, V; Koniari, I; Kontoprias, K; Perperis, A; Stavrou, K; Vogiatzi, C; Xanthopoulou, I	1
Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P	1
De Luca, L; De Servi, S; Menozzi, A	1
Turpie, AG	2
Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R	1
Calcagno, S; Sardella, G	1
Aradi, D; Komócsi, A	1
Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z	1
Cuisset, T; De Palma, R; James, S; Jüni, P	1
Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo Silberman, S; Sideris, G; Voicu, S	1
Abbate, R; Antoniucci, D; Bellandi, B; Capodanno, D; Carrabba, N; Comito, V; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R	1
Aylward, PE; Camuglia, AC; Hammett, CJ; Waddell-Smith, KE	1
Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Morange, P; Pankert, M; Quilici, J	1
Fauchère, I; Schreiber, P; Wyss, C	1
Crivera, C; Dea, K; Fields, LE; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, JR	1
Vengoechea, F	1
Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM	1
Ahmad, H; Arbab-Zadeh, A; Borer, JS; Garg, A; Garg, J; Krishnamoorthy, P; Lavie, CJ; Lichstein, E; Mukherjee, D; Sharma, A	1
Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L	1
Belle, L; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Delarche, N; El Mahmoud, R; Elhadad, S; Etienne, CS; Henry, P; Leclercq, F; Montalescot, G; Motreff, P; Pouillot, C; Rangé, G; Silvain, J; Van Belle, E; Varenne, O; Vicaut, E	1
Anderson, JL; Goto, S; Huo, Y; Jeong, YH; Levine, GN; Mega, JL; Smith, SC; Taubert, K	1
Messori, A	1
Lhermusier, T; Waksman, R	1
Jiang, M; You, JH	1
Holper, EM; Luna, M	1
Bultas, J	1
Scirica, BM; Shimada, YJ	1
Steg, PG; Wiviott, SD	1
Bonello, L; Cluzel, M; Dignat-George, F; Frere, C; Gaubert, M; Guieu, R; Hasan, A; Kerbaul, F; Laine, M; Mancini, J; Michelet, P; Paganelli, F; Thuny, F	1
Bolognese, L; Brown, E; Dudek, D; Hamm, C; LeNarz, L; Miller, DL; Montalescot, G; Motovska, Z; Tanguay, JF; Ten Berg, J; Widimsky, P	1
Ahsan, CH; Ali, ML; Amin, MN; Chowdhury, MZ; Haq, MM; Karim, MR; Khan, SR; Mansur, M; Millat, MH; Rashid, MA	1
Bangalore, S; Bavishi, C; Messerli, FH; Panwar, S	1
Angiolillo, DJ; Franchi, F	1
Parker, WA; Storey, RF	1
Yavelov, IS	1
Alberts, MJ; Hanley, DF; Serebruany, VL	1
Barker, CM; Price, MJ	1
Sosnowski, C	1
Angiolillo, DJ; Bass, TA; Bates, ER	1
Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD	1
Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF	1
Preobrazhenskiĭ, DV	1
Farkouh, ME; Fuster, V	1
Wiviott, SD	1
Dachs, R; Darby-Stewart, A; Graber, MA	1
De Servi, S; Mariani, G; Mariani, M	1
Angiolillo, DJ; Bhatt, DL; Gurbel, PA; Jennings, LK	1
Toth, PP	1
Faxon, DP; Freedman, JE	1
Giugliano, RP; Thomas, D	1
Sabatine, MS	1
Darius, H	1
Angiolillo, DJ; Capranzano, P; Ferreiro, JL	1
Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP	1
Marzot, F; Pengo, V	1
Das, K; Das, P; Koshy, SK; Robinson, A	1
Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD	1
Boyle, AJ; Yong, CM	1
Rees, C; Spinler, SA	1
Serebruany, VL	5
Eberli, FR; Roffi, M	1
Brandt, JT; Ernest II, CS; Farid, NA; Jakubowski, JA; Jin, Y; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	1
Arora, R; Jawad, E; Khosla, S; Pahwa, H; Singh, M; Singh, S	1
Eagle, K; Gurm, HS	1
Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A	1
Wallentin, L	1
Baker, WL; White, CM	1
Duggan, ST; Keating, GM	1
Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD	1
Ajani, AE; Gurvitch, R; Wilson, W	1
Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C	1
Schömig, A	1
Antman, EM; Bates, ER; Braunwald, E; Close, SL; Hautvast, RW; Mega, JL; Michelson, AD; Murphy, SA; O'Donoghue, ML; Rozenman, Y; Sabatine, MS; Shen, L; Ver Lee, PN; Wiviott, SD	1
Morrow, T	1
Stewart, RA	1
Collet, JP; Montalescot, G	1
Menon, V; Raymond, C	1
Franchini, M; Mannucci, PM	1
Abu-Fadel, M; Norgard, NB	1
Granger, CB; Lopes, RD	1
Eshaghian, S; Kaul, S; Shah, PK	1
Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE	1
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J	1
Dobesh, PP	1
Baker, WL; Reinhart, KM; White, CM	1
Farid, NA; Kurihara, A; Wrighton, SA	1
Lazar, LD; Lincoff, AM	1
del Río, A; Heras, M	1
Guerra, DR; Tcheng, JE	1
Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S	1
Bal dit Sollier, C; Barthélémy, O; Beygui, F; Cohen, R; Collet, JP; Drouet, L; Henry, P; Lim, P; Luo, J; Marshall, D; Meuleman, C; Montalescot, G; Petitjean, H; Sideris, G	1
Stone, GW	1
Solomon, S; Vacek, JL	1
Serebruany, V	2
Islam, AM; Patel, PM	1
Fareed, J; Jeske, WP; Mousa, SA	1
Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ	1
Bareiss, P; Kessler, L; Morel, O; Ohlmann, P	1
Abbate, R; Crea, F; De Servi, S; Filippi, E; Gensini, GF; Golinos, P; Savonitto, S	1
April, JH; Ernest, CS; Farid, NA; Li, YG; Ni, L; Payne, CD; Rohatagi, S; Small, DS; Winters, KJ	1
Neumann, FJ	1
Amin, AP; Marso, SP	1
Carballo, D; Keller, PF; Roffi, M	1
Erdem, G; Flather, MD; Geisler, T	1
Bagust, A; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Fleeman, N; Greenhalgh, J; Kolamunnage-Dona, R; McLeod, C; Proudlove, C; Saborido, CM	1
Freeman, MK	1
Diamond, GA; Kaul, S	1
Floyd, JS; Serebruany, VL	1
Devabhakthuni, S; Seybert, AL	1
Antman, EM; Braunwald, E; Wiviott, SD	2
Boonbaichaiyapruck, S; Ge, J; Goh, YS; Hong, BK; Hou, CJ; Pinton, P; Zhu, J	1
Gratsianskiĭ, NA	1
Pakhomov, IaM	1
Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM	1
Aïssaoui, N; Danchin, N	1
Antman, EM; Braunwald, E; Gibson, CM; Giugliano, R; Mohanavelu, S; Pride, YB; Tung, P; Wiviott, SD; Zorkun, C	1
Antman, EM; Braunwald, E; Close, SL; Mega, JL; Sabatine, MS; Shen, L; Simon, T; Walker, JR; Wiviott, SD	1
Abbate, R; Giusti, B	1
Chung, H; George, E; Hill, RA; Longson, C; Stevens, A	1
Abu-Fadel, MS; Dib, C; Hanna, EB	1
Abbate, A; Agostoni, P; Angiolillo, DJ; Biondi-Zoccai, G; Gaita, F; Lotrionte, M; Romagnoli, E; Sangiorgi, G; Sheiban, I; Testa, L; Valgimigli, M	1
Laizure, SC; Parker, RB	1
Angiolillo, DJ; Costigan, TM; Deraad, R; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF	1
Fletcher, B; Thalinger, KK	1
Farid, NA; Jakubowski, JA; Konkoy, CS; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	1
Antman, EM; Baracioli, L; Braunwald, E; Giugliano, RP; Heuer, H; Lotan, C; Merkely, B; Murphy, SA; Ruff, CT; Schersten, F; Seabro-Gomes, R; Wiviott, SD	1
Armani, AM	1
Capodanno, D; Tamburino, C	1
Frey, N; Ivandic, B	1
Farhan, S; Höchtl, T; Huber, K; Wojta, J	1
Lancellotti, P	1
Weitz, JI	1
Ağırbaşlı, M; Cinçin, A; Güvenç, H	1
Eikelboom, JW; Eriksson, BI; Quinlan, DJ	1
Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD	1
Arora, R; Chandrasekar, S; Loomba, R; Shah, P	1
Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M	1
Smetana, GW; Srour, JF	1
Ageno, W; Romualdi, E	1
Braunwald, E; Steffel, J	1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Silber, S; Steiger, H; Weil, J; Zugck, C	1
Baty, SR; Griffith, CB; Phillippe, HM	1
Bolognese, L; Dudek, D; Goedicke, J; Goldstein, P; Hamm, C; Luo, J; Miller, DL; Montalescot, G; Tanguay, JF; ten Berg, J; Widimsky, P	1
Chitose, T; Hokimoto, S; Kaikita, K; Ogawa, H; Ono, T; Tsujita, K; Yamamoto, K	1
Alexander, D; Jeremias, A	1
Bode, C; Braunwald, E; Burton, P; Cook-Bruns, N; Gibson, CM; Goto, S; Mega, JL; Plotnikov, A; Sun, X; Verheugt, F	1
Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M	1
Cattaneo, GJ; Cattaneo, M; Podda, GM	1
Moliterno, DJ; Rajan, L	1
Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC	1
Ernest, CS; Li, YG; Luo, J; Macias, WL; Ni, L; Riesmeyer, JS; Rohatagi, S; Salazar, DE; Small, DS; Weerakkody, GJ; Wrishko, RE	1
Böhm, M; Schirmer, SH	1
Martin, MT; Nutescu, EA; Spinler, SA	1
Fadda, V; Maratea, D; Messori, A; Passaro, D	1
Alexopoulos, D; Davlouros, P; Dimitropoulos, G; Hahalis, G; Mylona, P; Panagiotou, A; Perperis, A; Tsigkas, G; Xanthopoulou, I	1
Carballo, D; Carballo, S; Keller, PF; Roffi, M	1
Abbate, A; Agostoni, P; Biondi-Zoccai, G; D'Ascenzo, F; Modena, MG	1
Ait-Mokhtar, O; Barnay, P; Bonello, L; Bonello, R; Cabassome, E; Camilleri, E; Camoin-Jau, L; Cheneau, E; Collet, F; de Labriolle, A; Dignat-George, F; Jouve, B; Maillard, L; Mancini, J; Paganelli, F; Pansieri, M; Peyre, JP; Rossi, P; Wittenberg, O	1
Alber, HF; Frick, M; Huber, K; Pachinger, O	1
Antman, EM; Braunwald, E; Desai, N; Murphy, SA; Musumeci, G; Ragosta, M; Wiviott, SD	1
Arya, R; Patel, JP; Roberts, LN	1
Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J	1
Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D	1
Close, SL; Erlinge, D; Jakubowski, JA; Leishman, AG; Riesmeyer, JS	1
Armero, S; Berbis, J; Bonello, L; Bonello-Burignat, C; Camoin-Jau, L; Collet, F; Dignat-George, F; Jacquin, L; Lemesle, G; Ostorero, M; Paganelli, F; Pansieri, M	1
D'Urbano, M; De Servi, S; Navarese, EP; Savonitto, S	1
Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J	2
Bae, JP; Cohen, DJ; Graham, JB; Magnuson, EA; Mauskopf, JA; Meadows, ES; Ramaswamy, K; Zagar, AJ	1
Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Finzi, J; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J	1
Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Cohen, M; Cook-Bruns, N; Fox, KA; Gibson, CM; Goto, S; Mega, JL; Murphy, SA; Plotnikov, AN; Schneider, D; Sun, X; Verheugt, FW; Wiviott, SD	1
Ohman, EM; Roe, MT	2
Basra, SS; Lakkis, NM; Tsai, P	1
Aradi, D; Atar, D; Kuliczkowski, W; Serebruany, VL	1
Braunwald, E	1
Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL	1
Janknegt, R; Ruiters, L; Ten Cate, H	1
Burton, P; Gibson, M; Moore, K; Mueck, W; Plotnikov, A; Rossenu, S; Stuyckens, K; Vermeulen, A; Xu, XS	1
Gurbel, PA; Jeong, YH; Ohman, EM; Tantry, US	1
Mackay, SM; Tcheng, JE	1
Soff, GA	1
Contractor, H; Ruparelia, N	1
Khemasuwan, D; Suramaethakul, N	1
Lip, GY; Shantsila, A	1
Campbell, JA; Davis, EM; Knezevich, JT; Packard, KA	1
Favaloro, EJ; Lippi, G	1
Askari, AT; Stephens, JC	1
Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES	1
Dick, A; Druce, I; Froeschl, M; Glover, C; Gollob, MH; Goncalves, S; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, E; Roberts, JD; So, DY; Stewart, A; Wells, GA	1
Harding, SA; Johnston, LR; La Flamme, AC; Larsen, PD; Michel, JM; Simmonds, MB	1
James, S; Varenhorst, C	1
Morais, J	1
Bouras, G; Deftereos, S; Giannopoulos, G; Kossyvakis, C; Panagopoulou, V; Pyrgakis, V; Stefanadis, C	1
Gibson, CM; Gopalakrishnan, L; Kohli, P; Kumar, V; Rastogi, U; Singh, P	1
Angiolillo, DJ; Azmoon, S	1
Lyseng-Williamson, KA	1
Augoustides, JG	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Paganelli, F; Uhry, S	1
Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA	1
Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ	2
Díez, JG; Kuritzky, L	1
Heptinstall, S; Joshi, R; Wijeyeratne, YD	1
Ahmad, S; Storey, RF	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A	1
Bhatt, DL; Kar, S	1
Barn, K; Steinhubl, SR	1
Carrié, D; Garcia, C; Lhermusier, T; Mejean, S; Sié, P; Voisin, S	1
Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I	1
Pollack, CV	1
Atar, D; Serebruany, VL	1
Limper, U; Lynch, J	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Collet, F; Dignat-George, F; Jouve, B; Laine, M; Lemesle, G; Maillard, L; Mancini, J; Michelet, P; Paganelli, F; Pansieri, M; Rossi, P; Wittenberg, O	1
Angiolillo, DJ; Tello-Montoliu, A; Tomasello, SD	1
Price, MJ	2
Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ	1
Damman, P; de Winter, RJ; Fox, KA; Wallentin, L	1
Brown, PM; Gladding, P; Panattoni, L; Te Ao, B; Webster, M	1
Costopoulos, C; Gorog, DA; Kukreja, N; Niespialowska-Steuden, M	1
Ardissino, D; Casella, G; Magnani, G; Pavesi, PC	1
Esmon, CT	1
Graf, L; Tsakiris, DA	1
Alessi, MC; Bonnet, JL; Castelli, C; Cayla, G; Collet, JP; Cuisset, T; Kerneis, M; Montalescot, G; Morange, PE; O'Connor, SA; Quilici, J; Silvain, J	1
Alessi, MC; Beguin, S; Bonnet, JL; Cuisset, T; Dubois, N; Dutour, A; Gaborit, B; Loosveld, M; Loundou, AD; Morange, PE; Moro, PJ; Quilici, J	1
Brasselet, C; Duval, S	1
Aalbers, J	1
Beer, J; Gebhard, C	1
Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C	1
Badimon, JJ; Elmariah, S; Fuster, V; Giannarelli, C; Jakubowski, JA; Santos-Gallego, C; Sartori, S; Small, DS; Viles-Gonzalez, JF; Vorchheimer, DA; Zafar, MU	1
Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G	1
Bolognese, L; De Servi, S	1
Bonello, L; Dignat-George, F; Doddo Siddo, MN; Laine, M; Paganelli, F	1
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A	1
Fitchett, DH	1
Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K	1
Kent, KM; Laynez, A; Lindsay, J; Pichard, AD; Sardi, G; Satler, LF; Suddath, WO; Torguson, R; Waksman, R; Xue, Z	1
Bevilacqua, M; Cirillo, P; D'Anna, C; De Rosa, R; Di Gioia, G; Galasso, G; Niglio, T; Piccolo, R; Piscione, F; Strisciuglio, T	1
Angiolillo, DJ; Costigan, TM; DeRaad, R; Duvvuru, S; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF	1
Alexopoulos, D; Damelou, A; Davlouros, P; Hahalis, G; Mavronasiou, E; Plakomyti, TE; Theodoropoulos, KC; Xanthopoulou, I	1
Cenci, C; Cioni, G; Gensini, GF; Giusti, B; Lombardi, A; Marcucci, R	1
Alessi, MC; Beguin, S; Bonnet, JL; Castelli, C; Cuisset, T; Fourcade, L; Gaborit, B; Grosdidier, C; Loosveld, M; Morange, PE; Moro, PJ; Quilici, J; Saut, N	1
Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R	1
Fareed, J; Jeske, W; Thethi, I	1
Massberg, S; Orban, M; Sibbing, D	1
Dantzler, DM; Lynch, DR; Zhao, D	1
Eraso, LH; Merli, GJ; Perez, A	1
Daly, RL; Dhutia, AJ; Ecob, R; Howgego, KE; Judge, HM; Mehra, S; Morton, AC; Storey, RF; Sumaya, W	1
Goto, S; Tomiya, A	1
Maddox, TM	1
Bakhai, A; Barrett, A; Davies, A; Graham-Clarke, P; Schmitt, C; Sculpher, M	1
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N	1
Xie, H; Ye, Y; Zhang, S; Zhao, X	1
Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD	1
Bhatt, DL	1
Di Sciascio, G; Pasceri, V; Patti, G	1
Paulus, W; Riggert, J; von Lewinski, F	1
Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD	1
Harenberg, J; Wehling, M	1
Eikelboom, JW; Hankey, GJ; Langton, PE	1
De Servi, S; Lettino, M	1
Califf, RM; Fox, KA; Mahaffey, KW; Patel, MR; Piccini, JP	1
Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD	1
Alvarez, W	1
Haber, SL; Riley, AB; Tafreshi, MJ	1

Reviews

171 review(s) available for thiophenes and Acute Coronary Syndrome

Article	Year
Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China. Journal of cardiovascular pharmacology, 2017, Volume: 70, Issue:6 Topics: Acute Coronary Syndrome; China; Clopidogrel; Drug Discovery; Drug Resistance; Humans; Phenylacetates; Platelet Aggregation Inhibitors; Prodrugs; Thiophenes; Ticlopidine	2017
[Contribution of the new oral anticoagulants to the treatment of acute coronary syndrome]. Medicina clinica, 2012, Volume: 139 Suppl 2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2012
Rivaroxaban for the treatment of acute coronary syndromes. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:7 Topics: Acute Coronary Syndrome; Anticoagulants; Drug Approval; Drug Interactions; Europe; Humans; Morpholines; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration	2013
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs. Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2013, Volume: 41, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2013
Emerging antithrombotic drugs for acute coronary syndrome. Expert opinion on emerging drugs, 2013, Volume: 18, Issue:3 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Fibrinolytic Agents; Humans; Lactones; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Thiophenes	2013
Use of antiplatelet drugs in the treatment of acute coronary syndromes. Cardiovascular & hematological disorders drug targets, 2013, Volume: 13, Issue:2 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgraduate medicine, 2013, Volume: 125, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
New oral anticoagulants after acute coronary syndrome. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism	2013
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. The Canadian journal of cardiology, 2013, Volume: 29, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
Use of antiplatelet agents in patients with atherosclerotic disease. Postgraduate medicine, 2013, Volume: 125, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2013
Dual antiplatelet therapy -- management in general practice. Australian family physician, 2013, Volume: 42, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:2 Topics: Acute Coronary Syndrome; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism	2014
[Differentiated antiplatelet therapy for acute coronary syndromes]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2014
New antithrombotics for secondary prevention of acute coronary syndrome. Clinical cardiology, 2014, Volume: 37, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coronary Thrombosis; Dabigatran; Hemorrhage; Humans; Imines; Lactones; Morpholines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Thrombin	2014
Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials. Polskie Archiwum Medycyny Wewnetrznej, 2013, Volume: 123, Issue:11 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2013
Anticoagulation and antiplatelet therapy in acute coronary syndromes. Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2014
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome. The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine	2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2014
Rivaroxaban: a review of its use in acute coronary syndromes. Drugs, 2014, Volume: 74, Issue:4 Topics: Acute Coronary Syndrome; Administration, Oral; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome	2014
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor	2014
Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2014
Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes. Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Israel; Piperazines; Platelet Aggregation Inhibitors; Population Groups; Prasugrel Hydrochloride; Reproducibility of Results; Thiophenes; Ticagrelor	2014
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. British journal of clinical pharmacology, 2014, Volume: 78, Issue:4 Topics: Acute Coronary Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes	2014
New antiplatelet agents in the treatment of acute coronary syndromes. Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban]. Journal des maladies vasculaires, 2014, Volume: 39, Issue:3 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzamides; Blood Coagulation; Embolism; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia; Thrombosis	2014
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Mar-20, Volume: 9, Issue:11 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Vitamin K	2014
Efficacy and safety of prasugrel in acute coronary syndrome patients. Clinical biochemistry, 2014, Volume: 47, Issue:7-8 Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2014
The role of rivaroxaban in atrial fibrillation and acute coronary syndromes. Journal of cardiovascular pharmacology and therapeutics, 2014, Volume: 19, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Drug Costs; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2014
The newer direct oral anticoagulants: a practical guide. Clinical medicine (London, England), 2014, Volume: 14, Issue:2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2014
Rivaroxaban in acute coronary syndromes--is it prime time? Expert review of cardiovascular therapy, 2014, Volume: 12, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes	2014
Optimal aspirin dose in acute coronary syndromes: an emerging consensus. Future cardiology, 2014, Volume: 10, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thiophenes; Ticagrelor	2014
Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. Vascular health and risk management, 2014, Volume: 10 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome	2014
The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial. Cardiovascular therapeutics, 2014, Volume: 32, Issue:5 Topics: Acute Coronary Syndrome; Anticoagulants; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes	2014
Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood, 2014, Jul-31, Volume: 124, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Genetic Testing; Humans; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2014
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clinic proceedings, 2014, Volume: 89, Issue:7 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2014
Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. Expert review of cardiovascular therapy, 2014, Volume: 12, Issue:8 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Drug Approval; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Thiophenes	2014
The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Anticoagulants; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Thiophenes	2014
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome]. Praxis, 2014, Sep-03, Volume: 103, Issue:18 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine	2014
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2014
Role of oral factor Xa inhibitors after acute coronary syndrome. Cardiology, 2014, Volume: 129, Issue:4 Topics: Acute Coronary Syndrome; Administration, Oral; Azepines; Benzamides; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome	2014
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? American heart journal, 2014, Volume: 168, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin	2014
Prasugrel hydrochloride for the treatment of acute coronary syndromes. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4 Topics: Acute Coronary Syndrome; Animals; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2015
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine	2015
Use of novel antiplatelet agents in acute coronary syndromes. Current atherosclerosis reports, 2015, Volume: 17, Issue:3 Topics: Acute Coronary Syndrome; Animals; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes	2015
[Anticoagulant therapy in secondary prevention of coronary events]. Vnitrni lekarstvi, 2014, Volume: 60, Issue:12 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin	2014
Long-term management and unmet needs after an acute coronary syndrome event. The American journal of cardiology, 2015, Mar-14, Volume: 115, Issue:5 Suppl Topics: Acute Coronary Syndrome; Defibrillators, Implantable; Fibrinolytic Agents; Humans; Medication Adherence; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Prescriptions; Thiophenes; Time Factors	2015
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet (London, England), 2015, Jul-18, Volume: 386, Issue:9990 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. The American journal of cardiology, 2015, Sep-01, Volume: 116, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2015
[Practical Aspects of the Use of Oral Anticoagulant Rivaroxaban for the Prevention of Adverse Outcomes After Acute Coronary Syndrome]. Kardiologiia, 2016, Volume: 56, Issue:4 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Humans; Morpholines; Rivaroxaban; Thiophenes	2016
Clinical profile of prasugrel, a novel thienopyridine. American heart journal, 2008, Volume: 156, Issue:2 Suppl Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes	2008
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. Journal of interventional cardiology, 2008, Volume: 21, Issue:4 Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine	2008
The top 4 advances in antithrombotic care in the last year. Thrombosis research, 2008, Volume: 123 Suppl 1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2008
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel? Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2008
Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI? American family physician, 2008, Dec-01, Volume: 78, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2008
Advances in antiplatelet therapy: agents in clinical development. The American journal of cardiology, 2009, Feb-02, Volume: 103, Issue:3 Suppl Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Signal Transduction; Thiophenes; Ticagrelor; Treatment Outcome	2009
The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Postgraduate medicine, 2009, Volume: 121, Issue:1 Topics: Acute Coronary Syndrome; Aspirin; Humans; Life Style; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Thiophenes	2009
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. Critical pathways in cardiology, 2009, Volume: 8, Issue:1 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome	2009
Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2009
Prasugrel for the treatment of patients with acute coronary syndrome. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2009
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Future cardiology, 2009, Volume: 5, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2009
Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism. Current vascular pharmacology, 2010, Volume: 8, Issue:1 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Venous Thromboembolism	2010
Review of prasugrel for the secondary prevention of atherothrombosis. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Thrombosis; Ticlopidine	2009
Diabetes and acute coronary syndromes. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine	2009
Prasugrel: a novel antiplatelet therapy for acute coronary syndromes. Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:3 Topics: Acute Coronary Syndrome; Animals; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Thiophenes	2009
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European heart journal, 2009, Volume: 30, Issue:16 Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine	2009
Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombosis	2009
Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Drugs, 2009, Aug-20, Volume: 69, Issue:12 Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Tissue Distribution; Young Adult	2009
Prasugrel: a novel platelet ADP P2Y receptor antagonist. Cardiovascular therapeutics, 2009,Fall, Volume: 27, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Blood Platelets; Evidence-Based Medicine; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes	2009
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (London, England), 2009, Sep-19, Volume: 374, Issue:9694 Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2009
Dual antiplatelet therapy in coronary artery disease: a case-based approach. Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:11 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine	2009
New antiplatelet agents: why they are needed. European journal of internal medicine, 2009, Volume: 20, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Propionates; Pyridines; Thiophenes; Ticagrelor	2009
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vascular health and risk management, 2009, Volume: 5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2009
Advances in antiplatelet treatment for acute coronary syndromes. Heart (British Cardiac Society), 2010, Volume: 96, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2009
Prasugrel: a critical comparison with clopidogrel. Pharmacotherapy, 2009, Volume: 29, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Drug Inverse Agonism; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States	2009
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. Journal of clinical pharmacology, 2010, Volume: 50, Issue:2 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2010
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9 Suppl 1 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Prasugrel: Clinical development and therapeutic application. Advances in therapy, 2009, Volume: 26, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Thrombosis; Ticlopidine	2009
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine	2010
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Kidney Failure, Chronic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2010
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis, 2010, Volume: 212, Issue:2 Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Glycoproteins; Humans; Models, Biological; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thromboplastin; Thrombosis; Ticlopidine	2010
[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel]. Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:2 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2010
Acute coronary syndrome in the patient with diabetes: is the management different? Current cardiology reports, 2010, Volume: 12, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine	2010
Diabetes and acute coronary syndrome. Minerva medica, 2010, Volume: 101, Issue:2 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Diabetic Angiopathies; Endothelium, Vascular; Hemorrhage; Humans; Hypoglycemic Agents; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes	2010
What goes into a major acute coronary syndrome trial and what will future trials look like? Current cardiology reports, 2010, Volume: 12, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom	2010
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Economic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quality of Life; Quality-Adjusted Life Years; Risk Assessment; Thiophenes; Ticlopidine; United Kingdom	2010
Thienopyridine antiplatelet agents: focus on prasugrel. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2010, Volume: 25, Issue:4 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Treatment Outcome	2010
Prasugrel as a potential cancer promoter: review of the unpublished data. Archives of internal medicine, 2010, Jun-28, Volume: 170, Issue:12 Topics: Acute Coronary Syndrome; Humans; Incidence; Neoplasms; Periodicals as Topic; Piperazines; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Factors; Thiophenes; United States	2010
[Antiplatelet therapy in coronary heart disease. Some problems and achivements]. Kardiologiia, 2010, Volume: 50, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2010
Prasugrel. Circulation, 2010, Jul-27, Volume: 122, Issue:4 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
[Platelet inhibition with prasugrel]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:31-32 Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogrel; Coronary Artery Disease; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine	2010
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine	2010
A new era for antiplatelet therapy in patients with acute coronary syndrome. The American journal of the medical sciences, 2010, Volume: 340, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome	2010
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. International journal of cardiology, 2011, Aug-04, Volume: 150, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Treatment Outcome	2011
A comparison of the metabolism of clopidogrel and prasugrel. Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Thiophenes; Thrombosis; Ticlopidine	2010
Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention. Critical care nurse, 2010, Volume: 30, Issue:5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2010
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clinical pharmacokinetics, 2010, Volume: 49, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes	2010
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. Critical pathways in cardiology, 2010, Volume: 9, Issue:4 Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Thiophenes; Ticlopidine; Treatment Outcome; United States	2010
[New approaches and indications for the analysis of platelet function in cardiology]. Hamostaseologie, 2011, May-02, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
New anticoagulant agents in acute coronary syndromes. Heart (British Cardiac Society), 2011, Volume: 97, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Cyclic N-Oxides; Fondaparinux; Hirudins; Humans; Morpholines; Peptide Fragments; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes	2011
[Novel agents in antiplatelet therapy]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2010
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annual review of medicine, 2011, Volume: 62 Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K	2011
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Standard of Care; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
The need for novel anticoagulation therapy in acute coronary syndrome. American journal of therapeutics, 2013, Volume: 20, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Cyclic N-Oxides; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; Morpholines; Naphthalenes; Polysaccharides; Propionates; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin	2013
[Current options to manage clopidogrel poor responsiveness]. Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Triple therapy in hospitalized patients: facts and controversies. Journal of hospital medicine, 2011, Volume: 6, Issue:9 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hospitalization; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin	2011
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:4 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drugs, Investigational; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Venous Thromboembolism	2011
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European heart journal, 2011, Volume: 32, Issue:16 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2011
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2011
Triple therapy: boon or bane for high-risk CV patients? The Journal of family practice, 2011, Volume: 60, Issue:4 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Warfarin	2011
Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors. Journal of cardiology, 2011, Volume: 58, Issue:1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis	2011
Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Biological Availability; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes	2011
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2011
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists]. Recenti progressi in medicina, 2011, Volume: 102, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? Current cardiology reports, 2011, Volume: 13, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine	2011
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. European heart journal, 2011, Volume: 32, Issue:18 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2011
[Update on anti-platelet therapy]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:23 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Thrombolytic Therapy; Ticagrelor	2011
Ticagrelor for acute coronary syndrome? Drug and therapeutics bulletin, 2011, Volume: 49, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. Clinical therapeutics, 2011, Volume: 33, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:15-16 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine	2011
Anticoagulating obese patients in the modern era. British journal of haematology, 2011, Volume: 155, Issue:2 Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin	2011
TRITON and beyond: new insights into the profile of prasugrel. Cardiovascular therapeutics, 2012, Volume: 30, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Time Factors; Treatment Outcome	2012
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Current medical research and opinion, 2011, Volume: 27, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Antiplatelet options for secondary prevention in acute coronary syndromes. Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine	2011
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. Journal of the American College of Cardiology, 2011, Nov-22, Volume: 58, Issue:22 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia	2011
Unstable angina and non-ST elevation myocardial infarction. American journal of respiratory and critical care medicine, 2012, May-01, Volume: 185, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2012
A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
InforMatrix: ADP antagonists in acute coronary syndromes. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Information Services; Drugs, Generic; Evidence-Based Medicine; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2 Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticlopidine	2012
A new generation of oral direct anticoagulants. Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2012
Advances in antiplatelet therapy for acute coronary syndromes. Postgraduate medical journal, 2012, Volume: 88, Issue:1041 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2012, Volume: 18, Issue:5 Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin	2012
Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome. Pharmacotherapy, 2012, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Coronary Artery Disease; Hemorrhage; Humans; Imines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticagrelor	2012
Acute coronary syndromes: identifying the appropriate patient for prasugrel. Postgraduate medicine, 2012, Volume: 124, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Secondary Prevention; Thiophenes; Ticlopidine	2012
Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)? Current cardiology reports, 2012, Volume: 14, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Hemorrhage; Humans; Myocardial Ischemia; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor	2012
Current antiplatelet options for NSTE-ACS patients. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants? Current clinical pharmacology, 2012, Volume: 7, Issue:3 Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Clinical Trials as Topic; Drug Discovery; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome	2012
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:7 Topics: Acute Coronary Syndrome; Administration, Oral; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Interactions; Factor Xa; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Myocardial Infarction; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thrombosis	2012
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2013
Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors. Journal of cardiothoracic and vascular anesthesia, 2012, Volume: 26, Issue:4 Topics: Acute Coronary Syndrome; Anesthesia, Conduction; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Hospital practice (1995), 2012, Volume: 40, Issue:2 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2012
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thrombosis and haemostasis, 2012, Volume: 108, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Meeting new challenges with antiplatelet therapy in primary care. The Journal of family practice, 2012, Volume: 61, Issue:6 Suppl Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Primary Health Care; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor	2012
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes. Expert review of clinical pharmacology, 2012, Volume: 5, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Development and clinical use of prasugrel and ticagrelor. Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin	2012
A brief review of the past and future of platelet P2Y12 antagonist. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
New oral anticoagulants in the ED setting: a review. The American journal of emergency medicine, 2012, Volume: 30, Issue:9 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2012
Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome. Future cardiology, 2012, Volume: 8, Issue:4 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug Approval; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2012
Prasugrel. Advances in cardiology, 2012, Volume: 47 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clinical Trials as Topic; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Diabetic Angiopathies; Drug Interactions; Humans; Patient Selection; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Thiophenes	2012
Genetic considerations. Advances in cardiology, 2012, Volume: 47 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Genome-Wide Association Study; Genotype; Humans; Liver; Pharmacogenetics; Phenotype; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2012
Novel oral anticoagulants in acute coronary syndrome. International journal of cardiology, 2013, Sep-10, Volume: 167, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes	2013
What did we learn from new oral anticoagulant treatment? Thrombosis research, 2012, Volume: 130 Suppl 1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis	2012
Anticoagulant treatment: the end of the old agents? Swiss medical weekly, 2012, Volume: 142 Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Rivaroxaban; Stroke; Thiophenes; Thromboembolism	2012
[Platelet inhibitors in clinical practice]. Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Approval; Drug Interactions; Drug Resistance; Drugs, Investigational; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor	2012
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thrombosis and haemostasis, 2013, Volume: 109, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Potential role of rivaroxaban in patients with acute coronary syndrome. Drug design, development and therapy, 2012, Volume: 6 Topics: Acute Coronary Syndrome; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Intracranial Hemorrhages; Morpholines; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Warfarin	2012
Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome. Angiology, 2014, Volume: 65, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticagrelor	2014
Antiplatelets in acute coronary syndrome: personal perspectives. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidol; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor	2012
Metabolic differences of current thienopyridine antiplatelet agents. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Inactivation, Metabolic; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine	2013
Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice. Hamostaseologie, 2013, Volume: 33, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor	2013
Implications of new anticoagulants in primary practice. International journal of clinical practice, 2013, Volume: 67, Issue:2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2013
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes. Postgraduate medicine, 2013, Volume: 125, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
Smoking and prasugrel. International journal of cardiology, 2013, Sep-30, Volume: 168, Issue:2 Topics: Acute Coronary Syndrome; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Smoking; Thiophenes	2013
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Seminars in thrombosis and hemostasis, 2008, Volume: 34, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Glycine; Humans; Infusions, Parenteral; Morpholines; Oligosaccharides; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Venous Thromboembolism	2008
Will prasugrel supersede clopidogrel for acute coronary syndromes? The Medical journal of Australia, 2008, Apr-07, Volume: 188, Issue:7 Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine	2008
Rivaroxaban, an oral direct factor Xa inhibitor. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Animals; Anticoagulants; Atrial Fibrillation; Binding Sites; Clinical Trials as Topic; Comorbidity; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Rats; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin	2008
Prasugrel: a novel antiplatelet agent. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11 Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine	2008

Trials

78 trial(s) available for thiophenes and Acute Coronary Syndrome

Article	Year
Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. The American journal of medicine, 2017, Volume: 130, Issue:9 Topics: Acute Coronary Syndrome; Aged; Albuminuria; Analysis of Variance; Biomarkers; Cause of Death; Comorbidity; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Oxazoles; Patient Discharge; Percutaneous Coronary Intervention; Peroxisome Proliferator-Activated Receptors; Predictive Value of Tests; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Thiophenes	2017
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. Diabetes & vascular disease research, 2018, Volume: 15, Issue:1 Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Revascularization; Natriuretic Peptide, Brain; Oxazoles; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome	2018
Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. The Journal of clinical endocrinology and metabolism, 2018, 07-01, Volume: 103, Issue:7 Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Natriuretic Peptide, Brain; Oxazoles; Peptide Fragments; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Thiophenes	2018
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes care, 2018, Volume: 41, Issue:8 Topics: Acute Coronary Syndrome; Adiponectin; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Retrospective Studies; Stroke; Thiophenes; Treatment Outcome	2018
Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Drug Administration Schedule; Drug Resistance; Humans; Microfilament Proteins; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Time Factors; Treatment Outcome	2013
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes care, 2013, Volume: 36, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticagrelor; Ticlopidine	2013
Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thro Journal of the American College of Cardiology, 2013, May-07, Volume: 61, Issue:18 Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Prospective Studies; Rivaroxaban; Thiophenes; Thrombolytic Therapy; Treatment Outcome	2013
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. Journal of the American College of Cardiology, 2013, Jul-23, Volume: 62, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stents; Thiophenes; Thrombosis; Treatment Outcome	2013
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). The American journal of cardiology, 2013, Aug-15, Volume: 112, Issue:4 Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Endpoint Determination; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome	2013
Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study. Circulation. Cardiovascular interventions, 2013, Volume: 6, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Administration, Intravenous; Aged; Area Under Curve; Blood Flow Velocity; Coronary Circulation; Cross-Over Studies; Echocardiography, Doppler; Female; Greece; Humans; Least-Squares Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Single-Blind Method; Thiophenes; Ticagrelor; Treatment Outcome; Vasodilator Agents	2013
The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). Journal of the American College of Cardiology, 2013, Aug-27, Volume: 62, Issue:9 Topics: Acute Coronary Syndrome; Anticoagulants; Coronary Thrombosis; Double-Blind Method; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Myocardial Infarction; Randomized Controlled Trials as Topic; Reproducibility of Results; Rivaroxaban; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration	2013
Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy. Thrombosis research, 2013, Volume: 132, Issue:1 Topics: Abciximab; Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Administration Routes; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2013
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation, 2013, Aug-20, Volume: 128, Issue:8 Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2013
Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:3 Topics: Acute Coronary Syndrome; Aged; Antibodies, Antiphospholipid; Factor Xa Inhibitors; Female; Humans; Immunoglobulin M; Male; Middle Aged; Morpholines; Myocardial Infarction; Phosphorylcholine; Rivaroxaban; Stroke; Thiophenes	2014
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet (London, England), 2013, Aug-17, Volume: 382, Issue:9892 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2013
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). International journal of cardiology, 2013, Oct-15, Volume: 168, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine	2013
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11 Topics: Acute Coronary Syndrome; Aged; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Thiophenes	2013
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. American heart journal, 2013, Volume: 166, Issue:3 Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morbidity; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk Factors; Stroke; Thiophenes; Treatment Outcome	2013
Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:6 Topics: Acute Coronary Syndrome; Aged; Circadian Rhythm; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome	2013
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): Circulation. Cardiovascular interventions, 2013, Oct-01, Volume: 6, Issue:5 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Practice Guidelines as Topic; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2013
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit Journal of the American College of Cardiology, 2014, Jan-28, Volume: 63, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. Thrombosis and haemostasis, 2014, Volume: 111, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Diabetes Mellitus; Female; France; Humans; Hypoglycemic Agents; Insulin; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Pilot Projects; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome	2014
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). The American journal of cardiology, 2014, Jan-01, Volume: 113, Issue:1 Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Survival Rate; Sweden; Thiophenes; Ticlopidine; Treatment Outcome	2014
Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison. International journal of cardiology, 2013, Dec-10, Volume: 170, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome	2013
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:12 Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Risk Factors; Stroke; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REA Journal of cardiovascular translational research, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Coronary Thrombosis; Drug Administration Schedule; Fibrinolytic Agents; Germany; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Stents; Stroke; Thiophenes; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome	2014
A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:2 Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience. Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3 Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2014
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA, 2014, Apr-16, Volume: 311, Issue:15 Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk; Stroke; Survival Analysis; Thiophenes; Treatment Outcome	2014
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:7 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors	2014
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thrombosis research, 2014, Volume: 134, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Cytochrome P-450 CYP2C19; Female; Humans; Male; Pilot Projects; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticagrelor	2014
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. American heart journal, 2014, Volume: 168, Issue:1 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Smoking; Survival Rate; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United Kingdom; United States	2014
Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thrombosis and haemostasis, 2014, Sep-02, Volume: 112, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Female; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Treatment Outcome	2014
[The ACCOAST study]. Giornale italiano di cardiologia (2006), 2014, Volume: 15, Issue:5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Case-Control Studies; Coronary Angiography; Humans; Italy; Piperazines; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Research Design; Thiophenes; Time Factors; Treatment Outcome	2014
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine	2014
Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. American heart journal, 2014, Volume: 168, Issue:5 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Treatment Outcome	2014
Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes. The American journal of cardiology, 2015, Aug-01, Volume: 116, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome; Young Adult	2015
Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart (British Cardiac Society), 2015, Volume: 101, Issue:15 Topics: Acute Coronary Syndrome; Age Factors; Aged; Chi-Square Distribution; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Sex Factors; Thiophenes; Time Factors; Treatment Outcome	2015
Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention. Bangladesh Medical Research Council bulletin, 2013, Volume: 39, Issue:3 Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger. Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Secondary Prevention; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2008
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European heart journal, 2008, Volume: 29, Issue:20 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2008
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. Critical pathways in cardiology, 2009, Volume: 8, Issue:1 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome	2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European heart journal, 2009, Volume: 30, Issue:14 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi Circulation, 2009, Jun-02, Volume: 119, Issue:21 Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatine Kinase, MB Form; Death, Sudden, Cardiac; Double-Blind Method; Humans; Incidence; Kaplan-Meier Estimate; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Thiophenes; Ticlopidine; Time Factors; Troponin T	2009
The FDA prasugrel review: adjudication of myocardial infarction controversy. Cardiology, 2009, Volume: 114, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration	2009
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Current medical research and opinion, 2009, Volume: 25, Issue:8 Topics: Acute Coronary Syndrome; Adolescent; Adult; Antibiotics, Antitubercular; Drug Interactions; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Rifampin; Thiophenes; Young Adult	2009
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683 Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Myocardial Infarction; Proportional Hazards Models; Pyridines; Recurrence; Risk Reduction Behavior; Rivaroxaban; Safety; Statistics, Nonparametric; Stroke; Thiophenes; Treatment Outcome	2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla Journal of the American College of Cardiology, 2009, Aug-18, Volume: 54, Issue:8 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Stroke; Thiophenes; Ticlopidine	2009
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio American heart journal, 2009, Volume: 158, Issue:3 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thrombosis and haemostasis, 2010, Volume: 103, Issue:1 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Paris; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2010
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary. Postgraduate medicine, 2010, Volume: 122, Issue:1 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2010
Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. Journal of clinical pharmacology, 2011, Volume: 51, Issue:3 Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Biotransformation; Body Weight; Female; Half-Life; Humans; Male; Middle Aged; Models, Biological; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Young Adult	2011
Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Current medical research and opinion, 2010, Volume: 26, Issue:9 Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Algorithms; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine; Young Adult	2010
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. Journal of the American College of Cardiology, 2010, Sep-21, Volume: 56, Issue:13 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. International journal of cardiology, 2012, Mar-22, Volume: 155, Issue:3 Topics: Acute Coronary Syndrome; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome	2012
A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. American heart journal, 2011, Volume: 161, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Double-Blind Method; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Time Factors; Treatment Outcome	2011
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-c American heart journal, 2011, Volume: 161, Issue:5 Topics: Acute Coronary Syndrome; Adolescent; Adult; Anticoagulants; Coronary Angiography; Double-Blind Method; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Prospective Studies; Rivaroxaban; Thiophenes; Thrombolytic Therapy; Treatment Outcome; Young Adult	2011
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of clinical pharmacology, 2012, Volume: 52, Issue:6 Topics: Acute Coronary Syndrome; Age Factors; Aged; Biotransformation; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Hemorrhage; Humans; Incidence; Male; Models, Biological; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Severity of Illness Index; Thiophenes; Thrombosis	2012
High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. Journal of the American College of Cardiology, 2011, Jul-26, Volume: 58, Issue:5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Blood Platelets; Coronary Thrombosis; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; ROC Curve; Sensitivity and Specificity; Stents; Thiophenes	2011
Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. The American journal of cardiology, 2011, Oct-01, Volume: 108, Issue:7 Topics: Acute Coronary Syndrome; Aged; Brain Ischemia; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Treatment Outcome; United States	2011
Rivaroxaban in patients with a recent acute coronary syndrome. The New England journal of medicine, 2012, Jan-05, Volume: 366, Issue:1 Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes	2012
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. British journal of clinical pharmacology, 2012, Volume: 74, Issue:1 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Young Adult	2012
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet (London, England), 2012, May-05, Volume: 379, Issue:9827 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Carrier Screening; Genetic Testing; Genotype; Humans; Loss of Heterozygosity; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2012
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology, 2012, Jul-31, Volume: 60, Issue:5 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause of Death; Chest Tubes; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Retrospective Studies; Risk Adjustment; Thiophenes; Ticlopidine	2012
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. Journal of the American College of Cardiology, 2012, Jul-17, Volume: 60, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. The New England journal of medicine, 2012, Oct-04, Volume: 367, Issue:14 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine	2012
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA, 2012, Nov-07, Volume: 308, Issue:17 Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2012
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1 Topics: Acute Coronary Syndrome; Adult; Aspirin; Biotransformation; Blood Platelets; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemostasis; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Prasugrel Hydrochloride; Prospective Studies; Thiophenes	2013
Acute coronary syndrome and rivaroxaban: not so fast... Prescrire international, 2012, Volume: 21, Issue:132 Topics: Acute Coronary Syndrome; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes	2012
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2013
Safety and efficacy of prasugrel use in patients undergoing percutaneous coronary intervention and anticoagulated with bivalirudin. The American journal of cardiology, 2013, Feb-15, Volume: 111, Issue:4 Topics: Acute Coronary Syndrome; Antithrombins; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Retrospective Studies; Thiophenes; Treatment Outcome	2013
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thrombosis and haemostasis, 2013, Volume: 109, Issue:2 Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Substitution; Female; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Pharmacogenetics; Phenotype; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Treatment Outcome	2013
Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity. American heart journal, 2013, Volume: 165, Issue:1 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome	2013
Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine	2007
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi Lancet (London, England), 2008, Apr-19, Volume: 371, Issue:9621 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2008
[The TRITON-TIMI 38 trial]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2008
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys Journal of the American College of Cardiology, 2008, May-27, Volume: 51, Issue:21 Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine	2008

Other Studies

146 other study(ies) available for thiophenes and Acute Coronary Syndrome

Article	Year
Switching from prasugrel to clopidogrel: navigating in unknown waters. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2 Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2013
Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2 Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Substitution; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology, 2013, Volume: 124, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. The American journal of cardiology, 2013, Aug-01, Volume: 112, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Markov Chains; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine	2013
Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. International journal of cardiology, 2013, Oct-03, Volume: 168, Issue:3 Topics: Acute Coronary Syndrome; Blood Platelets; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Off-Label Use; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes	2013
Factors affecting residual platelet aggregation in prasugrel treated patients. Current pharmaceutical design, 2013, Volume: 19, Issue:28 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Cohort Studies; Drug Resistance; Female; Heart Diseases; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Models, Biological; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Smoking; Thiophenes	2013
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)]. MMW Fortschritte der Medizin, 2013, Apr-18, Volume: 155, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Industry; Drugs, Generic; Forecasting; Germany; Humans; National Health Programs; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circulation. Cardiovascular quality and outcomes, 2013, May-01, Volume: 6, Issue:3 Topics: Acute Coronary Syndrome; Aged; Blue Cross Blue Shield Insurance Plans; Contraindications; Drug Utilization; Drug Utilization Review; Female; Guideline Adherence; Humans; Insurance, Pharmaceutical Services; Male; Michigan; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Prospective Studies; Quality Improvement; Quality Indicators, Health Care; Registries; Risk Factors; Thiophenes; Time Factors; Treatment Outcome	2013
Prasugrel: the real-life perspective. Circulation. Cardiovascular quality and outcomes, 2013, May-01, Volume: 6, Issue:3 Topics: Acute Coronary Syndrome; Blue Cross Blue Shield Insurance Plans; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes	2013
Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013, Volume: 13, Issue:4 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Compliance; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Retrospective Studies; Thiophenes	2013
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Thrombosis and haemostasis, 2013, Volume: 110, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; United States	2013
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes. Thrombosis and haemostasis, 2013, Volume: 110, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; United States	2013
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel. The American journal of emergency medicine, 2013, Volume: 31, Issue:8 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine	2013
Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel. The American journal of emergency medicine, 2013, Volume: 31, Issue:8 Topics: Acute Coronary Syndrome; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine	2013
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Cardiology, 2013, Volume: 126, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2013
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. International journal of cardiology, 2013, Oct-12, Volume: 168, Issue:5 Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. Thrombosis and haemostasis, 2013, Volume: 110, Issue:5 Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cell Adhesion Molecules; Cell Separation; Clopidogrel; Enzyme-Linked Immunosorbent Assay; Feasibility Studies; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Ticlopidine	2013
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Hemorrhage; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition? JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8 Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
P2Y12 inhibition in patients with NSTEMI--can later be better? The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11 Topics: Acute Coronary Syndrome; Coronary Angiography; Female; Humans; Male; Piperazines; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Thiophenes	2013
Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives. Thrombosis and haemostasis, 2014, Volume: 111, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Coagulation Tests; Blood Platelets; Cost-Benefit Analysis; Decision Trees; Europe; Humans; Incidence; Markov Chains; Medication Adherence; Monte Carlo Method; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor	2014
Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Circulation. Cardiovascular quality and outcomes, 2013, Volume: 6, Issue:6 Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genetic Testing; Genotype; Health Personnel; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Sequence Deletion; Thiophenes; Ticlopidine	2013
Drug interactions with good old clopidogrel: case closed. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:12 Topics: Acute Coronary Syndrome; Calcium Channel Blockers; Clopidogrel; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. American heart journal, 2014, Volume: 167, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
P2Y12-based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy. JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine	2014
Reply: P2Y12-Based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy. JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine	2014
Smoking status and the effects of antiplatelet drugs. BMJ (Clinical research ed.), 2013, Oct-01, Volume: 347 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. Journal of the American College of Cardiology, 2014, Mar-25, Volume: 63, Issue:11 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2014
Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Annals of the rheumatic diseases, 2014, Volume: 73, Issue:6 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Thiophenes	2014
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Annals of internal medicine, 2014, Feb-18, Volume: 160, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Acute coronary syndromes: Aleglitazar trial findings reported. Nature reviews. Cardiology, 2014, Volume: 11, Issue:6 Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Oxazoles; Thiophenes	2014
Is it appropriate to compare the results from two clinical trials with one drug in common? Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2013
Evaluation of comparative treatment effects using indirect comparisons. Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2013
Evaluation of comparative treatment effects using indirect comparisons. Response. Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2013
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics". Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Japan; Marketing; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2014
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients. Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Economic Competition; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value. Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Drug Utilization; Evidence-Based Medicine; Humans; International Cooperation; Marketing; Patient Satisfaction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2014
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. International journal of cardiology, 2014, Jul-01, Volume: 174, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Direct oral anticoagulants in acute coronary syndrome. Seminars in hematology, 2014, Volume: 51, Issue:2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Ischemia; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes	2014
The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients. Journal of the American College of Cardiology, 2014, Jul-22, Volume: 64, Issue:3 Topics: Acute Coronary Syndrome; Cause of Death; Female; Humans; Male; Piperazines; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine	2014
Reply: The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients. Journal of the American College of Cardiology, 2014, Jul-22, Volume: 64, Issue:3 Topics: Acute Coronary Syndrome; Cause of Death; Female; Humans; Male; Piperazines; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine	2014
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States	2014
Will this trial change my practice? ACCOAST - early loading with a novel P2Y12 inhibitor in patients with an acute coronary syndrome. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:3 Topics: Acute Coronary Syndrome; Drug Administration Schedule; Evidence-Based Medicine; Hemorrhage; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Time Factors; Treatment Outcome	2014
Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests. International journal of cardiology, 2014, Sep-20, Volume: 176, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome	2014
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome. International journal of cardiology, 2014, Oct-20, Volume: 176, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Postoperative Care; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Retrospective Studies; Thiophenes; Thrombosis; Ticagrelor	2014
Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. International journal of cardiology, 2014, Oct-20, Volume: 176, Issue:3 Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Blood Platelets; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Treatment Outcome	2014
Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. International journal of cardiology, 2014, Oct-20, Volume: 176, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Body Mass Index; Female; Humans; Male; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor	2014
Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel. Journal of clinical pharmacy and therapeutics, 2014, Volume: 39, Issue:6 Topics: Acute Coronary Syndrome; Aged; Bayes Theorem; Clopidogrel; Cohort Studies; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ open, 2014, Oct-31, Volume: 4, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine	2014
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI. Global heart, 2014, Volume: 9, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Societies, Medical; Thiophenes; Ticagrelor; Ticlopidine; World Health Organization	2014
Cardiovascular safety of new oral anticoagulants: re-analysis of 27 randomized trials based on Bayesian network meta-analysis. British journal of clinical pharmacology, 2015, Volume: 80, Issue:1 Topics: Acute Coronary Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Thiophenes	2015
Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome. Prescrire international, 2014, Volume: 23, Issue:153 Topics: Acute Coronary Syndrome; Administration, Oral; Drug Dosage Calculations; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Patient Selection; Platelet Aggregation Inhibitors; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome	2014
Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention. JACC. Cardiovascular interventions, 2016, Feb-08, Volume: 9, Issue:3 Topics: Acute Coronary Syndrome; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2016
Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 2016, Sep-13, Volume: 134, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2016
Antiplatelet therapy in acute coronary syndromes. Current cardiology reports, 2008, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2008
[Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15]. Kardiologia polska, 2008, Volume: 66, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2008
[Prasugrel versus Clopidogrel in patients with acute coronary syndromes. Results of the TRITON-TIMI 38 trial]. Kardiologiia, 2008, Volume: 48, Issue:8 Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel. Circulation, 2008, Oct-14, Volume: 118, Issue:16 Topics: Acute Coronary Syndrome; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes	2008
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Facts and controversies of aspirin and clopidogrel therapy. American heart journal, 2009, Volume: 157, Issue:3 Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine	2009
Novel antiplatelet strategies in acute coronary syndromes. Cleveland Clinic journal of medicine, 2009, Volume: 76 Suppl 1 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
[New anticoagulants]. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:16 Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis	2009
Rivaroxaban in acute coronary syndromes: too soon to know? Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683 Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome	2009
Ticagrelor--is there need for a new player in the antiplatelet-therapy field? The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2009
Prasugrel, new platelet inhibitor, subject of formulary debates. Managed care (Langhorne, Pa.), 2009, Volume: 18, Issue:8 Topics: Acute Coronary Syndrome; Clinical Trials, Phase III as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Formularies as Topic; Humans; Managed Care Programs; Piperazines; Prasugrel Hydrochloride; Thiophenes	2009
Underestimation of the effect of bleeding in clinical trials. Lancet (London, England), 2009, Oct-03, Volume: 374, Issue:9696 Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Hemorrhage; Humans; Morpholines; Research Design; Rivaroxaban; Thiophenes; Treatment Outcome; Young Adult	2009
[New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome]. MMW Fortschritte der Medizin, 2009, Sep-03, Volume: 151, Issue:36 Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire international, 2009, Volume: 18, Issue:103 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2009
P2Y12 inhibitors: thienopyridines and direct oral inhibitors. Hamostaseologie, 2009, Volume: 29, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor	2009
Interpreting the TRITON results in light of the event adjudication process. Cardiology, 2010, Volume: 115, Issue:2 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes	2010
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. Journal of gastrointestinal cancer, 2009, Volume: 40, Issue:3-4 Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes	2009
Clopidogrel versus prasugrel: times are changing, but not for everyone. Pharmacotherapy, 2009, Volume: 29, Issue:12 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk. Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines. European heart journal, 2009, Volume: 30, Issue:23 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
The TRITON versus PLATO trials: differences beyond platelet inhibition. Thrombosis and haemostasis, 2010, Volume: 103, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug Circulation, 2010, Jan-05, Volume: 121, Issue:1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States	2010
Ticagrelor in ACS: redefining a new standard of care? Lancet (London, England), 2010, Jan-23, Volume: 375, Issue:9711 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2010
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge. Thrombosis and haemostasis, 2010, Volume: 103, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome	2010
Delays of event adjudication in the TRITON trial. Cardiology, 2010, Volume: 115, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary Restenosis; Data Collection; Disease-Free Survival; Hemorrhage; Myocardial Infarction; Observer Variation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Stents; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration	2010
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. Journal of cardiovascular pharmacology, 2010, Volume: 56, Issue:1 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
[Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course]. MMW Fortschritte der Medizin, 2010, Apr-01, Volume: 152, Issue:13 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiology; Clinical Trials as Topic; Clopidogrel; Emergencies; Fibrinolysis; Forecasting; Humans; Length of Stay; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors	2010
Prasugrel and cancer: an uncertain association or a credible risk that meaningfully alters the benefit-risk balance. Archives of internal medicine, 2010, Jun-28, Volume: 170, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Colorectal Neoplasms; Humans; Incidence; Lung Neoplasms; Mice; Myocardial Infarction; Neoplasms, Experimental; Piperazines; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2 Receptor Antagonists; Risk Factors; Stroke; Thiophenes; United States	2010
Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel. Critical care nurse, 2011, Volume: 31, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Treatment Outcome	2011
Mortality in the TRITON trial: update from the FDA prasugrel action package. The American journal of cardiology, 2010, Jul-15, Volume: 106, Issue:2 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Treatment Outcome	2010
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial]. Kardiologiia, 2010, Volume: 50, Issue:6 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel JACC. Cardiovascular interventions, 2010, Volume: 3, Issue:8 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Chi-Square Distribution; Coronary Angiography; Coronary Stenosis; Creatine Kinase, MB Form; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome; Up-Regulation; Vascular Patency	2010
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by O Circulation, 2010, Aug-24, Volume: 122, Issue:8 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome	2010
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (London, England), 2010, Oct-16, Volume: 376, Issue:9749 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2010
Response to antiplatelet treatment: from genes to outcome. Lancet (London, England), 2010, Oct-16, Volume: 376, Issue:9749 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine	2010
Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention: NICE technology appraisal guidance. Heart (British Cardiac Society), 2010, Volume: 96, Issue:17 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cost-Benefit Analysis; Evidence-Based Medicine; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes	2010
Price, pragmatism and ∇prasugrel. Drug and therapeutics bulletin, 2010, Volume: 48, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes	2010
Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial. International journal of cardiology, 2011, Jan-21, Volume: 146, Issue:2 Topics: Acute Coronary Syndrome; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Humans; Myocardial Ischemia; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes	2011
[Medication of the month. Prasugrel (Efient): potent thienopyridine antiplatelet agent]. Revue medicale de Liege, 2010, Volume: 65, Issue:11 Topics: Acute Coronary Syndrome; Coronary Thrombosis; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes	2010
Factor Xa and thrombin as targets for new oral anticoagulants. Thrombosis research, 2011, Volume: 127 Suppl 2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K	2011
[Prasugrel--oral (Efient)]. Journal de pharmacie de Belgique, 2010, Issue:4 Topics: Acute Coronary Syndrome; Drug Interactions; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis	2010
Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis. International journal of cardiology, 2011, Aug-04, Volume: 150, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor	2011
Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population. Journal of thrombosis and thrombolysis, 2011, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Diabetes Mellitus; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prevalence; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Thiophenes	2011
[Specificities of diabetes in acute coronary syndromes]. Revue medicale suisse, 2011, Jun-01, Volume: 7, Issue:297 Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Humans; Hypoglycemic Agents; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2011
Agreement between adjusted indirect comparison and simplified network meta-analyses on prasugrel and ticagrelor (Reply to Passaro et al. - Int J Cardiol 2011). International journal of cardiology, 2011, Sep-01, Volume: 151, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Randomized Controlled Trials as Topic; Thiophenes	2011
New anticoagulants: moving on from scientific results to clinical implementation. Annals of medicine, 2011, Volume: 43, Issue:8 Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K	2011
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome. Hospital practice (1995), 2011, Volume: 39, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Diagnostic Techniques and Procedures; Drug Therapy, Combination; Dyspnea; Emergency Service, Hospital; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes. The American journal of cardiology, 2011, Dec-15, Volume: 108, Issue:12 Topics: Acute Coronary Syndrome; Female; Gastrointestinal Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes	2011
Cost-effectiveness of prasugrel in a US managed care population. Journal of medical economics, 2012, Volume: 15, Issue:1 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cost Control; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Interviews as Topic; Male; Managed Care Programs; Middle Aged; Models, Economic; Outcome Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States	2012
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European heart journal, 2012, Volume: 33, Issue:10 Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine	2012
A new era in secondary prevention after acute coronary syndrome. The New England journal of medicine, 2012, Jan-05, Volume: 366, Issue:1 Topics: Acute Coronary Syndrome; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes	2012
Rivaroxaban (Xarelto) for acute coronary syndrome. The Medical letter on drugs and therapeutics, 2011, Dec-12, Volume: 53, Issue:1379-1380 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration	2011
Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thrombosis and haemostasis, 2012, Volume: 107, Issue:2 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clinical Protocols; Female; Humans; Male; Middle Aged; Observer Variation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Prevalence; Prospective Studies; Proton Pump Inhibitors; Thiophenes	2012
Toward a therapeutic window for antiplatelet therapy in the elderly. European heart journal, 2012, Volume: 33, Issue:10 Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:3 Topics: Acute Coronary Syndrome; American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fibrinolytic Agents; Humans; Lactones; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism	2012
Coagulopathies and thrombosis: usual and unusual causes and associations, part VI. Seminars in thrombosis and hemostasis, 2012, Volume: 38, Issue:2 Topics: Acute Coronary Syndrome; Altitude; Blood Coagulation Disorders; Coffee; Factor Xa Inhibitors; Heparin; Humans; Lipoproteins; Lymphatic Diseases; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis; Troponin; Venous Thrombosis; von Willebrand Diseases	2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy, 2012, Volume: 32, Issue:4 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Drugs, Generic; Genotype; Hemorrhage; Humans; Models, Economic; Models, Statistical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine	2012
Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes. International journal of cardiology, 2013, Aug-10, Volume: 167, Issue:3 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; New Zealand; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
[Anticoagulants and dual antiplatelet therapy combined, a challenge to our intelligence]. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2012, Volume: 31 Suppl 1 Topics: Acute Coronary Syndrome; Anticoagulants; Drug Therapy, Combination; Humans; Morpholines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Rivaroxaban; Thiophenes	2012
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Economics, Pharmaceutical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States	2012
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:9 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome. Heart advisor, 2010, Volume: 13, Issue:5 Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO? Thrombosis and haemostasis, 2012, Volume: 108, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor	2012
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia]. Der Anaesthesist, 2012, Volume: 61, Issue:8 Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive System Surgical Procedures; Drug Interactions; Hemorrhage; Humans; Male; Middle Aged; Pain, Postoperative; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine	2012
Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10 Topics: Acute Coronary Syndrome; Blood Platelets; Cell Adhesion Molecules; Coronary Thrombosis; Female; Follow-Up Studies; France; Hemorrhage; Humans; Kaplan-Meier Estimate; Linear Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome	2012
Letter by Damman et al regarding articles, "Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient d Circulation, 2012, Aug-28, Volume: 126, Issue:9 Topics: Acute Coronary Syndrome; Blood Platelets; Coronary Artery Bypass; Death, Sudden, Cardiac; Female; Humans; Male; Myocardial Infarction; Myocardial Revascularization; Piperazines; Randomized Controlled Trials as Topic; Thiophenes; Thrombolytic Therapy	2012
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. PharmacoEconomics, 2012, Nov-01, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Diagnosis-Related Groups; Drugs, Generic; Female; Genetic Testing; Hospital Costs; Hospitalization; Humans; Male; Middle Aged; Monte Carlo Method; Native Hawaiian or Other Pacific Islander; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Thiophenes; Ticlopidine	2012
Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. The Journal of thoracic and cardiovascular surgery, 2013, Volume: 145, Issue:4 Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Thiophenes; Ticlopidine	2013
[The ATLAS ACS 2-TIMI 51 study]. Giornale italiano di cardiologia (2006), 2012, Volume: 13, Issue:10 Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Double-Blind Method; Factor Xa Inhibitors; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes	2012
Prasugrel monitoring and bleeding in real world patients. The American journal of cardiology, 2013, Jan-01, Volume: 111, Issue:1 Topics: Acute Coronary Syndrome; Female; France; Humans; Incidence; Male; Middle Aged; Monitoring, Physiologic; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Postoperative Hemorrhage; Prasugrel Hydrochloride; Prognosis; Purinergic P2Y Receptor Antagonists; Thiophenes	2013
Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
[Role of new oral anticoagulants in interventional cardiology]. Annales de cardiologie et d'angeiologie, 2012, Volume: 61, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cardiac Surgical Procedures; Cardiology; Dabigatran; Humans; Morpholines; Percutaneous Coronary Intervention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome	2012
Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients. Cardiovascular journal of Africa, 2012, Volume: 23, Issue:9 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Electrocardiography; Expert Testimony; Humans; Morpholines; Myocardial Infarction; Practice Guidelines as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiophenes; Treatment Outcome	2012
Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition. JAMA, 2012, Nov-07, Volume: 308, Issue:17 Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Health Care Costs; Hemorrhage; Humans; Insurance, Health, Reimbursement; Kaplan-Meier Estimate; Markov Chains; Medicare; Models, Economic; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States	2013
Trilogy: in search of the lost ring. International journal of cardiology, 2013, Aug-20, Volume: 167, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Improved biological efficacy of prasugrel one month after an acute coronary syndrome. International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5 Topics: Acute Coronary Syndrome; Follow-Up Studies; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Time Factors; Treatment Outcome	2013
CYP2C192 and 17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:12 Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Risk Factors; Thiophenes	2012
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The American journal of cardiology, 2013, Mar-15, Volume: 111, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Chi-Square Distribution; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Statistics, Nonparametric; Thiophenes; Ticlopidine; Treatment Outcome	2013
Prasugrel versus clopidogrel for acute coronary syndromes. The New England journal of medicine, 2013, 01-10, Volume: 368, Issue:2 Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine	2013
Prasugrel versus clopidogrel for acute coronary syndromes. The New England journal of medicine, 2013, 01-10, Volume: 368, Issue:2 Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine	2013
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay. Thrombosis and haemostasis, 2013, Volume: 109, Issue:3 Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Area Under Curve; Cations; Citrates; Clopidogrel; Coronary Angiography; Female; Hematologic Tests; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Sodium Citrate; Thiophenes; Ticlopidine; Treatment Outcome	2013
High on-treatment platelet reactivity (HPR): what does it mean, and does it matter? Thrombosis and haemostasis, 2013, Volume: 109, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2013
Promise and peril of clinical decision support: translating medical evidence to the individual patient. Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1 Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. Journal of medical economics, 2013, Volume: 16, Issue:4 Topics: Acute Coronary Syndrome; Age Factors; Clopidogrel; Comorbidity; Cost-Benefit Analysis; Europe; Humans; Markov Chains; Models, Economic; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Turkey	2013
Effect of CYP2C192 and 17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. The American journal of cardiology, 2013, Apr-01, Volume: 111, Issue:7 Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Polymerase Chain Reaction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2013
Intensifying platelet inhibition--navigating between Scylla and Charybdis. The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
Prasugrel versus clopidogrel. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine	2008
Prasugrel versus clopidogrel. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine	2008
Prasugrel versus clopidogrel. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news. Cardiology, 2008, Volume: 111, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hematemesis; Hematuria; Hemorrhage; Humans; Intracranial Hemorrhages; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2008
For better or for worse: the future of antiplatelet therapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11 Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine	2008